| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/28/2014 | US8637081 Use of gelatin and a cross-linking agent for producing a cross-linking therapeutic composition |
| 01/28/2014 | US8637080 Rupturing controlled release device comprising a subcoat |
| 01/28/2014 | US8637079 Solid preparation comprising alogliptin and pioglitazone |
| 01/28/2014 | US8637078 Bilayer tablet comprising telmisartan and diuretic |
| 01/28/2014 | US8637077 Sustained-release preparation |
| 01/28/2014 | US8637076 Prednisolone salt formulations |
| 01/28/2014 | US8637075 Colostrum composition |
| 01/28/2014 | US8637074 Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product |
| 01/28/2014 | US8637073 Treatment of dependence withdrawal |
| 01/28/2014 | US8637072 Antimicrobial wound dressing comprising gel-forming fibers and specific ratio of silver to nitrate |
| 01/28/2014 | US8637071 Method for making medical devices having antimicrobial coatings thereon |
| 01/28/2014 | US8637070 Rapamycin formulations and methods of their use |
| 01/28/2014 | US8637069 Device and method for combining a treatment agent and a gel |
| 01/28/2014 | US8637068 Hypotensive prostamide-containing biodegradable intraocular implants and related methods |
| 01/28/2014 | US8637054 Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives |
| 01/28/2014 | US8637043 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 01/28/2014 | US8636993 Water-in-oil emulsions with anionic groups, compositions, and methods |
| 01/28/2014 | US8636985 Functional formulation in chewing gum |
| 01/28/2014 | US8636984 Aerosol formulation of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis |
| 01/28/2014 | US8636983 Aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis |
| 01/28/2014 | US8636982 Wax foamable vehicle and pharmaceutical compositions thereof |
| 01/28/2014 | US8636973 Method of producing pharmacologically pure crystals |
| 01/28/2014 | US8636684 Methods and systems for toxin delivery to the nasal cavity |
| 01/28/2014 | CA2779630C Combination of azelastine and steroids |
| 01/28/2014 | CA2731766C Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| 01/28/2014 | CA2723458C Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 01/28/2014 | CA2671461C Vesicles of self-assembling block copolymers and methods for making and using the same |
| 01/28/2014 | CA2659523C Multilayer orally disintegrating tablet |
| 01/28/2014 | CA2654522C Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient |
| 01/28/2014 | CA2652280C Polymers for functional particles |
| 01/28/2014 | CA2625856C Drug delivery systems |
| 01/28/2014 | CA2618974C Nanoemulsion compositions having anti-inflammatory activity |
| 01/28/2014 | CA2616877C Systems and methods for manufacturing liposomes |
| 01/28/2014 | CA2603069C Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates |
| 01/28/2014 | CA2594065C Transdermal, therapeutic system with activatable oversaturation and controlled permeation promotion |
| 01/28/2014 | CA2592030C Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| 01/28/2014 | CA2585779C In-situ forming implant for animals |
| 01/28/2014 | CA2580357C Non-adhesive elastic gelatin matrices |
| 01/28/2014 | CA2571897C Controlled extended drug release technology |
| 01/28/2014 | CA2565347C Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies |
| 01/28/2014 | CA2554030C Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders |
| 01/28/2014 | CA2533740C Biliquid foams, stable dispersions thereof and a corresponding process of manufacturing |
| 01/28/2014 | CA2484318C Warming and nonirritating lubricant antifungal gel compositions |
| 01/28/2014 | CA2469408C Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate |
| 01/28/2014 | CA2464867C Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
| 01/28/2014 | CA2430039C Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| 01/23/2014 | WO2014015334A1 System and methods for nanostructure protected delivery of treatment agent and selective release thereof |
| 01/23/2014 | WO2014015183A1 Ophthalmic formulation and method for ameliorating presbyopia |
| 01/23/2014 | WO2014015153A2 Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 |
| 01/23/2014 | WO2014015027A1 Liposomal compositions of epoxyketone-based proteasome inhibitors |
| 01/23/2014 | WO2014015016A1 Liposomal compositions of epoxyketone-based proteasome inhibitors |
| 01/23/2014 | WO2014014890A1 Targeted therapeutic nanoparticles |
| 01/23/2014 | WO2014014841A1 Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| 01/23/2014 | WO2014014766A1 Krill oil and reacted astaxanthin composition and associated method |
| 01/23/2014 | WO2014014753A1 Composition comprising an organic liquid diluent and a cellulose ether of very low viscosity |
| 01/23/2014 | WO2014014752A1 Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose |
| 01/23/2014 | WO2014014706A1 Nicotinamide derivate in the treatment of acute coronary syndrome |
| 01/23/2014 | WO2014014645A1 Systems and methods for oral administration of a therapy |
| 01/23/2014 | WO2014014434A1 Preparation for the treatment of tuberculosis |
| 01/23/2014 | WO2014014427A1 Modified release pharmaceutical tablet formulations |
| 01/23/2014 | WO2014014364A1 Injectable antibiotic formulations and their methods of use |
| 01/23/2014 | WO2014014363A1 Injectable antibiotic formulations and their methods of use |
| 01/23/2014 | WO2014014348A1 Gastro-retentive drug delivery system |
| 01/23/2014 | WO2014014271A1 Tablet comprising melissa officinalis folium extract for preventing or treating angiogenesis or mmp activity-mediated disease |
| 01/23/2014 | WO2014014150A1 Pharmaceutical composition comprising antiviral neuraminidase inhibitor and permeation enhancer for enhanced oral bioavailability |
| 01/23/2014 | WO2014014129A1 Solid preparation |
| 01/23/2014 | WO2014014010A1 Tablet having dry-ink film on surface thereof, and ink for inkjet printer |
| 01/23/2014 | WO2014013973A1 Printer and tablet |
| 01/23/2014 | WO2014013928A1 Stabilized solid preparation for internal use |
| 01/23/2014 | WO2014013903A1 Liquid composition containing taxane-based active ingredient, process for producing same, and liquid medicinal preparation |
| 01/23/2014 | WO2014013423A1 Glucosaline maintenance solution for pediatric parenteral administration |
| 01/23/2014 | WO2014013413A1 Hydrosoluble film having healing activity |
| 01/23/2014 | WO2014013195A1 Use of an amphoteric chelating agent for preventing contact allergies |
| 01/23/2014 | WO2014013194A1 Use of a cream that protects against the effects of aggressive chemical agents in contact with the skin |
| 01/23/2014 | WO2014013090A2 Formulation comprising amorphous fingolimod |
| 01/23/2014 | WO2014013044A1 Dry granulates of mesoporous silica powders |
| 01/23/2014 | WO2014013008A1 Gastro-resistant delayed release pharmaceutical form |
| 01/23/2014 | WO2014013006A1 Multilayered pharmaceutical formulation |
| 01/23/2014 | WO2014012805A1 Pharmaceutical compositions containing oligomeric lactic acid |
| 01/23/2014 | WO2014012653A1 Pharmaceutical patch for transdermal administration of tapentadol |
| 01/23/2014 | WO2014012652A1 Electric-field assisted administration of tapentadol |
| 01/23/2014 | WO2013175494A3 Controlled release pharmaceutical formulations of direct thrombin inhibitors |
| 01/23/2014 | WO2013168177A3 Osmotically controlled drug delivery systems |
| 01/23/2014 | WO2013167112A8 Composition for nasal application |
| 01/23/2014 | WO2012072256A3 Once daily formulation of lacosamide |
| 01/23/2014 | US20140024720 Pharmaceutical composition containing cyclobenzaprine suitable to intranasal administration |
| 01/23/2014 | US20140024669 Tamper resistant dosage forms |
| 01/23/2014 | US20140024615 Compositions and methods for preventing infectious diseases in females |
| 01/23/2014 | US20140024610 Nanoparticles loaded with chemotherapeutic antitumoral drug |
| 01/23/2014 | US20140024604 Glycopeptide phosphonate derivatives |
| 01/23/2014 | US20140023714 Hemostatic compositions |
| 01/23/2014 | US20140023711 Bioactive surface capable of genetically modifying biological cells or tissues and use thereof |
| 01/23/2014 | US20140023710 Milnacipran formulations |
| 01/23/2014 | US20140023709 Oral tablet compositions of dexlansoprazole |
| 01/23/2014 | US20140023708 Laminated tablet and manufacturing method therefor |
| 01/23/2014 | US20140023707 Co-Processed Carbohydrate System as a Quick-Dissolve Matrix for Solid Dosage Forms |
| 01/23/2014 | US20140023705 Dosage forms for oral administration and methods of treatment using the same |
| 01/23/2014 | US20140023704 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| 01/23/2014 | US20140023703 Nanocapsules with a polymer shell |
| 01/23/2014 | US20140023700 Cyclic peptide and conjugate thereof for binding to keratinocytes |